Gylden Pharma Limited

Active09955881 Private limited company

Incorporated: 18 January 2016 (10 years)
Previously known as: Emergex Vaccines Holding Limited (until 16 October 2024)
This list may be incomplete. See all names on Companies House
Industry: Research and experimental development on biotechnology (72110)
Directors: Fabricio Klerynton Marchini
Tony Flanagan
Poh Hui Chia
all 8 directors
Controlled by: Thomas William Rademacher
Accounts type: Unaudited abridged
Region: South East
Address: 4 & 5 Dunmore Court
Wootton Road
Abingdon
OX13 6BH

Filing status

Accounts due: 31 December 2026
Last accounts: 31 March 2025
Conf. stmt due: 21 August 2027
Last conf. stmt: 7 August 2026

Charges

Total: 6
Outstanding: 5
Part satisfied: 0
Satisfied: 1

Officers 8 active

Officer details are public data from the Companies House register.

Marchini, Fabricio Klerynton

Director · Appointed 27 August 2026

Brazilian

Born December 1979 (46)

Flanagan, Tony

Director · Appointed 9 July 2026

Irish

Born February 1966 (60)

Chia, Dr Poh Hui

Director · Appointed 5 January 2024

Singaporean

Born March 1983 (43)

Jackson, David Clifford

Director · Appointed 17 August 2022

Also at Burges Grove Management Company Limited · more companies

British

Born December 1948 (77)

Tufaro, Frank

Director · Appointed 17 August 2022

American

Born December 1954 (71)

Seng Chin, Finian Tan, Dr

Director · Appointed 3 September 2019

Singaporean

Born March 1962 (64)

Moore-Thornicroft, Storme Jo-Anne

Director · Appointed 18 January 2016

British

Born March 1974 (52)

Rademacher, Thomas William, Professor

Director · Appointed 18 January 2016

Also at Lascaux Pharmaceuticals Limited, Sylus Pharmaceuticals Ltd · more companies

American

Born May 1950 (76)

Officer history (11 former)

27 August 2026

Resigned De Godoi Mattos Ferreira, Ricardo, Dr as Director

27 August 2026

Appointed Marchini, Fabricio Klerynton as Director

9 July 2026

Appointed Flanagan, Tony as Director

14 November 2025

Resigned Pagani, Sergio as Director

3 September 2024

Resigned Rake, Michael Derek Vaughn, Sir as Director

5 January 2024

Appointed Chia, Dr Poh Hui as Director

5 January 2024

Resigned Lim, Xinhong, Dr as Director

27 September 2023

Appointed De Godoi Mattos Ferreira, Ricardo, Dr as Director

8 December 2022

Appointed Rake, Michael Derek Vaughn, Sir as Director

17 August 2022

Appointed Jackson, David Clifford as Director

17 August 2022

Resigned Dong, Yixiang as Director

17 August 2022

Resigned Sedgwick, Anthony David, Professor as Director

17 August 2022

Appointed Tufaro, Frank as Director

16 April 2021

Appointed Sedgwick, Anthony David, Professor as Director

4 January 2021

Resigned Philip, Mohan, Dr as Director

24 September 2020

Appointed Lim, Xinhong, Dr as Director

8 December 2019

Resigned Jackson, David Clifford as Director

22 November 2019

Resigned King, David Anthony, Sir as Director

3 September 2019

Appointed Seng Chin, Finian Tan, Dr as Director

1 August 2018

Appointed Pagani, Sergio as Director

23 April 2018

Resigned Oakes, Herbert as Director

15 March 2018

Appointed King, David Anthony, Sir as Director

4 January 2018

Resigned Bradman, Godfrey Michael as Director

10 August 2017

Appointed Dong, Yixiang as Director

1 April 2017

Appointed Philip, Mohan, Dr as Director

25 August 2016

Appointed Bradman, Godfrey Michael as Director

25 August 2016

Appointed Oakes, Herbert as Director

25 August 2016

Appointed Jackson, David Clifford as Director

18 January 2016

Appointed Moore-Thornicroft, Storme Jo-Anne as Director

18 January 2016

Appointed Rademacher, Thomas William, Professor as Director

Ownership 1 active

People and entities with significant control, from the Companies House PSC register

Thomas William Rademacher

Individual · Notified 6 April 2016

Has significant influence or control

American

Born May 1950 (76)

Holdings 1

Companies where Gylden Pharma Limited is registered as a person with significant control

Gylden Limited

Owns 75–100% of shares

Dissolved

Financials

Balance sheet as at 31 March 2025 · unaudited abridged accounts

Net Assets: (£3,337,403)
Cash: £294,382
Employees: 36

Debt Ratio: 272%
Current Ratio: 0.1x

Trend

Net Assets

Balance sheet detail

	2025	2024
Fixed Assets	£1,333,211	£4,459,014
Current Assets	£611,207	£2,796,832
Debtors	£316,825	£2,279,820
Cash	£294,382	£517,012
Creditors (< 1 year)	£4,120,784	£5,211,622
Net Current Assets	(£3,509,577)	(£2,414,790)
Net Assets	(£3,337,403)	£1,799,977
Shareholder Funds	(£3,337,403)	£1,799,977

Filings

Recent filings only. See the full history on Companies House

Date	Description	Made Up To
1 September 2026	Appointment of a director
27 August 2026	Appointment of a director
27 August 2026	Termination of appointment of a director
20 August 2026	Confirmation statement with updates	7 August 2026
20 August 2026	Registration of a charge